Coroner Report Links Richard Norton Peptides Overdose to Fatal Heart Attack

Coroner Findings on Richard Norton Peptides Overdose

An official coroner report has concluded that 75-year-old actor and martial artist Richard Norton passed away following a heart attack brought on by administering double his prescribed amount of medication. Melbourne-based coroner David Ryan determined that the fatality was directly triggered by an injection of richard norton peptides after the film fighter took quantities exceeding his doctor's instructions.

Two days prior to passing away on March 30, Norton informed a medical practice nurse that he had been taking twice the advised amount of CJC1295 and Ipamorelin. Although the nurse instructed him to revert to the correct amount the following week, the tragedy occurred shortly after he administered another dose that same evening, leading to his collapse and subsequent hospitalisation.

Background and Medical Consultation

Norton had initially visited Dr. Jerzy Muchnicki in March 2025 while recovering from shoulder surgery, citing fatigue and pain when expressing interest in peptide therapy. The physician reviewed his history, discussed the experimental nature and risks of the treatment, and had Norton sign a consent form before prescribing the substances.

While online influencers and wellness promoters frequently market peptides for faster healing, glowing skin, improved sleep, and longevity, regulators maintain strict oversight concerns. In Norton's case, the coroner faulted the prescribing doctor for authorizing a replacement vial without checking practice nurse records that noted the patient's incorrect dosing history, and for failing to speak directly with Norton to verify appropriate use.

Broader Regulatory Context

The coroner's findings highlight growing scrutiny surrounding the grey market for unapproved peptides. Coroner Ryan has recommended that Australia's Therapeutic Goods Administration implement stricter regulations on these substances.

Meanwhile, international health authorities continue to evaluate various peptide compounds. Compounding pharmacies have recently received clearance to produce certain peptide varieties in other regions, though official scientific bodies note that available safety and efficacy data remain limited.

Sources: NBC News, E! News, Nine.com.au, Entertainment Weekly.